← Eichor
Condition: Ptcl Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Ptcl

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
Phase 3 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05931263SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
Phase 3 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT06122389Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Phase 1 · 10 location(s) · SciTech Development, Inc. · NCT04234048Go-CHOP as the Frontline Therapy for PTCL
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT05963347Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07372352Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06151106Genotype-guided Treatment in Newly Diagnosed PTCL
Phase 1/Phase 2 · 1 location(s) · Ruijin Hospital · NCT05675813Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
Phase 2 · 6 location(s) · University of Virginia · NCT04747236A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
Phase 1/Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06855823Linperlisib Combined With Chidamide in Patients With PTCL
Phase 1/Phase 2 · 6 location(s) · Yanyan Liu · NCT06421948A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Phase 1/Phase 2 · 37 location(s) · Dren Bio · NCT05475925Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07074457Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Phase 2 · 6 location(s) · Great Novel Therapeutics Biotech & Medicals Corporation · NCT05833724Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
Phase 1/Phase 2 · 1 location(s) · University of Virginia · NCT03161223To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Phase 3 · 69 location(s) · Acrotech Biopharma Inc. · NCT06072131Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07072221RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.
Phase 2 · 1 location(s) · Xianmin Song, MD · NCT06468267Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
Phase 3 · 1 location(s) · Fudan University · NCT07300514Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Pe
Phase 2 · 1 location(s) · Liling Zhang · NCT05976997Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Speci
Phase 3 · 34 location(s) · Corvus Pharmaceuticals, Inc. · NCT06561048Golidocitinib Plus CHOP in Newly Diagnosed PTCL
Phase 1/Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06739265Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Phase 1 · 20 location(s) · Ono Pharmaceutical Co., Ltd. · NCT05079282Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort
Phase N/A · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT07253129Polyspecific Antibodies in Lymphoproliferative T-cell Disorders
Phase 1/Phase 2 · 8 location(s) · Xenothera SAS · NCT06495723A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Phase 1 · 22 location(s) · Incyte Corporation · NCT07195916Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL
NA · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT06509945AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Phase 1/Phase 2 · 37 location(s) · AstraZeneca · NCT06137144CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
Phase 1/Phase 2 · 4 location(s) · Beijing GoBroad Hospital · NCT06925464CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
Phase 1/Phase 2 · 3 location(s) · Beijing GoBroad Hospital · NCT07022964Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06909474
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.